A phase II randomized trial of metastasis-directed therapy with alpha emitter radium-223 in men with oligometastatic castration-resistant prostate cancer (MEDAL)

BACKGROUND: The significance of metastasis-directed therapy for oligometastatic prostate cancer has been widely discussed, and targeted therapy for progressive sites is a feasible option as a multidisciplinary treatment for castration-resistant prostate cancer (CRPC). When oligometastatic CRPC with...

Descripción completa

Detalles Bibliográficos
Autores principales: Yoshida, Soichiro, Takahara, Taro, Arita, Yuki, Ito, Masaya, Hayakawa, Sara, Oguchi, Tomohiko, Komai, Yoshinobu, Numao, Noboru, Yuasa, Takeshi, Inoue, Masaharu, Ushijima, Hiroki, Kudo, Shigehiro, Shimano, Yasumasa, Nakamura, Yuki, Uchida, Yusuke, Uehara, Sho, Tanaka, Hajime, Yaegashi, Hiroshi, Izumi, Kouji, Yokoyama, Minato, Matsuoka, Yoh, Yoshioka, Yasuo, Konishi, Koji, Nakanishi, Katsuyuki, Nagahara, Akira, Hirakawa, Akihiro, Koike, Ryuji, Koga, Fumitaka, Nishimura, Kazuo, Mizokami, Atsushi, Yonese, Junji, Kageyama, Yukio, Yoshimura, Ryoichi, Fujii, Yasuhisa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9987040/
https://www.ncbi.nlm.nih.gov/pubmed/36879257
http://dx.doi.org/10.1186/s12894-023-01202-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9987040/
https://www.ncbi.nlm.nih.gov/pubmed/36879257
http://dx.doi.org/10.1186/s12894-023-01202-z

Ejemplares similares